ABSCI CORP (ABSI) is up +11.85% in the latest session. Our newswire has captured 2 stories on ABSI across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 53/100).
ABSI stock fell 6.93% to $9.00 on Tuesday. The decline followed the company’s announcement that it will report third-quarter 2026 financial and operating results before market open on November 12. The move occurred despite a recent price target increase from JPMorgan.
Absci Corporation, a clinical-stage biopharmaceutical company advancing therapeutics designed with generative AI, announced it will release its Q3 2026 results on November 12. The company scheduled an 8:00 a.m. ET webcast to discuss business developments and outlook. The announcement highlighted the firm’s generative AI drug-creation platform.
In the same period, JPMorgan raised its price target for ABSI to $15 from $14. Other analysts also maintained positive stances, with HC Wainwright & Co. reiterating a Buy rating with a $16 price target and Needham reiterating a Buy rating with an $11 price target. Despite these ratings, the stock traded lower in the session.
The stock opened at $9.75, a 0.8% gap up from the prior close of $9.67. It reached a session high of $9.78 at 7:05 a.m. ET before sliding to a session low of $9.00 at 3:30 p.m. ET. Volume stood at 1.7 million shares, which is 0.4 times the three-month daily average.
Fundamentals show a market cap of $1.7 billion. The company is unprofitable with a trailing twelve-month EPS of -0.80 and revenue down 62.3% over the same period. The stock has a beta of 2.28. Over the last 52 weeks, the price range is $2.24 to $12.05. In the last eight sessions, the stock moved down 13.9% from $11.23 to $9.67. On October 13, 2026, the stock printed six fresh 52-week highs and 13 fresh 52-week lows.
Investors will focus on the November 12 earnings release and the accompanying webcast. The upcoming report will provide details on the company’s generative AI platform and future outlook.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
VANCOUVER, Wash. and NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the...
VANCOUVER, Wash. and NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the...
ABSCI CORP (ABSI) is up +11.85% in the latest session. Our newswire has captured 2 stories on ABSI across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 53/100). The most recent driver: "Absci to Participate in Upcoming Investor Conferences" (GlobeNewswire).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of ABSI coverage reads 53/100 over 2 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on ABSI: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ABSI move explainers: 2026-10-13 · 2026-09-02